Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

biogen netherlands b.v. - nusinersen natríum - vöðvaáfall, mænu - Önnur lyf í taugakerfinu - spinraza er ætlað til meðferðar á 5q spítala.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

recordati netherlands b.v. - tivozanib - krabbamein, nýrnafrumur - Æxlishemjandi lyf - fotivda er ætlað fyrir fyrstu línuna meðferð fullorðinn sjúklinga með langt skert klefi krabbamein (rcc) og fyrir fullorðna sjúklinga sem eru vegfr og hana ferli hemil-barnalegt eftir sjúkdóms eftir einn meðferð áður með frumuboða meðferð fyrir háþróaður rcc. meðferð háþróaður skert klefi krabbamein.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - brexpiprazole - geðklofa - psycholeptics - meðferð geðklofa.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - samgena cd34+ klefi inniheldur íbúa sem inniheldur blóðmyndandi stofnfrumur transduced með lentiglobin bb305 lentiviral vektor kóðun beta-a-t87q-glóbín gene - beta-thalassemia - other hematological agents - zynteglo er ætlað fyrir meðferð sjúklinga 12 ára og eldri með blóðgjöf-háð beta thalassaemia (tdt) sem hafa ekki β0/β0 arfgerð, fyrir hvern skurðaðgerðir stafa klefi (hsc) ígræðslu er rétt en hvítra manna antigen (hla)-samsvörun tengjast hsc gjafa er ekki í boði.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

alnylam netherlands b.v. - givosiran - porphyrias, lifur - Ýmsum meltingarvegi og efnaskipti vörur - meðferð bráð lifur porfýría (wells fargo) í fullorðnir og unglingar á aldrinum 12 ára og eldri.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - hundar - fyrir meðferð ekki resectable, ekki sjúklingum (sem sviðsetning) undir húð mastur klefi æxli staðsett á eða fjarlæga að olnboga eða skuldir, og ekki resectable, ekki sjúklingum húð mastur klefi æxli í hunda.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - blæðandi hiti, ebóla - bóluefni - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - blæðandi hiti, ebóla - bóluefni - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - Önnur meltingarvegi og efnaskipti vörur, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.

Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - bóluefni - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.